Kodiak Sciences Inc.
biotech company
KOD Nasdaq
ISIN US50015M1099 SEC CIK 1468748 LEI 254900IXI5NI8C9OQE24
Follow Kodiak Sciences
Weekly email: filings, results
Net income
−$66.2M
−7.8% vs same quarter last year
EPS, diluted
−$1.05
+9.5% vs same quarter last year
Operating cash flow
−$43.9M
−33.4% vs same quarter last year
Operating income
−$67.1M
−7.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$230M |
| FY24 | −$176.2M |
| FY23 | −$260.5M |
| FY22 | −$333.8M |
| FY21 | −$267M |
| FY20 | −$133.1M |
| FY19 | −$47.4M |
| FY18 | −$41.4M |
| FY17 | −$27.9M |
| FY16 | −$17.1M |
| FY15 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$136.5M |
| FY24 | −$117.7M |
| FY23 | −$195.5M |
| FY22 | −$243.5M |
| FY21 | −$199.3M |
| FY20 | −$87.2M |
| FY19 | −$39.6M |
| FY18 | −$29.1M |
| FY17 | −$17.9M |
| FY16 | −$16.8M |
| FY15 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | $0 |
| FY17 | $0 |
| FY16 | $4K |
| FY15 | - |